Shares of CRISPR ... Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. Management is developing two next-generation CAR-T therapy candidates ...
Zacks.com on MSN14d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...
Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...
Moreover, Crispr Therapeutics has reported encouraging initial clinical data from its Phase I/II trial of CTX112, an allogeneic CAR-T therapy for CD19-positive B-cell malignancies, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback